Uthman Olalekan A, Katoto Patrick D M C, Anjorin Seun S, Marais Thinus, Amiche Amine, Nachega Jean B
Warwick Centre for Global Health Research, Division of Health Sciences, Warwick Medical School, The University of Warwick, Coventry, UK.
Centre for Evidence-Based Health Care, Division of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch University, Cape Town, South Africa.
Hum Vaccin Immunother. 2025 Dec;21(1):2481802. doi: 10.1080/21645515.2025.2481802. Epub 2025 Mar 25.
Africa's participation in vaccine trials has historically been limited, but the COVID-19 pandemic highlighted the need for greater involvement. This study explores vaccine clinical development in Africa, emphasizing its importance for global health security. Using a scoping review and bibliometric analysis, we examined 662 vaccine trials conducted before, during, and after the pandemic. The analysis revealed a significant increase in vaccine trials after 2018 and particularly following the end of the COVID-19 pandemic in May 2023. Most trials focused on viral infections and were single-country studies. Pharmaceutical company sponsors funded most of the earlier trials, with increased government and academic involvement post-2020. Despite progress, challenges remain in the geographic distribution of trials, the number of government-supported studies, and the diversity of conditions studied. Addressing these gaps is crucial to bolstering Africa's role in global vaccine development.
从历史上看，非洲参与疫苗试验的程度有限，但新冠疫情凸显了加大参与力度的必要性。本研究探讨了非洲的疫苗临床开发情况，强调了其对全球卫生安全的重要性。通过范围综述和文献计量分析，我们考察了疫情之前、期间和之后进行的662项疫苗试验。分析显示，2018年之后，尤其是在2023年5月新冠疫情结束后，疫苗试验显著增加。大多数试验聚焦于病毒感染，且为单国研究。制药公司赞助商为早期的大多数试验提供了资金，2020年之后政府和学术界的参与有所增加。尽管取得了进展，但在试验的地理分布、政府支持研究的数量以及所研究病症的多样性方面，挑战依然存在。弥补这些差距对于加强非洲在全球疫苗开发中的作用至关重要。
